Regeneron Pharmaceuticals, Inc. (LON: 0R2M)
London
· Delayed Price · Currency is GBP · Price in USD
713.88
+6.59 (0.93%)
Dec 23, 2024, 6:40 PM BST
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.72B USD in the quarter ending September 29, 2024, with 10.65% growth. This brings the company's revenue in the last twelve months to $13.85B, up 5.72% year-over-year. In the year 2023, Regeneron Pharmaceuticals had annual revenue of $13.12B with 7.76% growth.
Revenue (ttm)
$13.85B
Revenue Growth
+5.72%
P/S Ratio
n/a
Revenue / Employee
$1.03M
Employees
13,450
Market Cap
60.06B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 30, 2023 | 13.12B | 944.30M | 7.76% |
Dec 30, 2022 | 12.17B | -3.90B | -24.26% |
Dec 30, 2021 | 16.07B | 7.57B | 89.14% |
Dec 30, 2020 | 8.50B | 1.94B | 29.58% |
Dec 30, 2019 | 6.56B | 1.41B | 27.44% |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 30, 2016 | Pro | Pro | Pro |
Dec 30, 2015 | Pro | Pro | Pro |
Dec 30, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRegeneron Pharmaceuticals News
- 4 days ago - Regeneron reports positive results for two anti-coagulant drugs - Seeking Alpha
- 4 days ago - Regeneron Pharmaceuticals Inc (REGN) Announces Positive Phase 2 Results for Novel ... - GuruFocus
- 4 days ago - Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results - GlobeNewsWire
- 5 days ago - Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 days ago - Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study - Benzinga
- 6 days ago - Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion - Seeking Alpha
- 6 days ago - Regeneron Pharmaceuticals Inc (REGN) Announces Positive Phase 3 Trial Results for EYLEA HD - GuruFocus
- 6 days ago - Regeneron Pharmaceuticals Inc (REGN) Achieves High Sustainability Rankings - GuruFocus